ArticleEuropean journal of clinical pharmacology2026
Pharmacogenomic screening strategy and indicative screening efficiency for antithyroid drug-induced agranulocytosis in the Southern Han Chinese.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeAntithyroid drug-induced agranulocytosis (ATDIA) is a life-threatening adverse drug reaction with strong population-specific genetic predispositions. This study aimed to develop a pharmacogenomic risk-stratification model and to evaluate the indicative screening efficiency of targeted pretherapeutic screening in the mainland Southern Han Chinese population.
methodsThis retrospective case-control study enrolled 171 patients with Graves' disease: 36 with ATDIA, 59 with antithyroid drug-induced neutropenia (ATDIN), and 76 ATD-tolerant controls. High-throughput genotyping of HLA-B, HLA-DRB1, and 32 candidate single nucleotide polymorphisms (SNPs) was performed. Genetic associations, predictive modeling with 1,000-resample bootstrap internal validation, and indicative economic impact estimations were evaluated.
resultsHLA-B*38:02 (OR = 48.667, 95% CI = 12.660-187.088) and HLA-DRB1*08:03 (OR = 11.698, 95% CI = 4.452-30.737) were strongly associated with ATDIA, but not with ATDIN. Six independent SNPs remained significantly associated with ATDIA. A multifactorial predictive model incorporating HLA-B*38:02, HLA-DRB1*08:03, and rs1811197 showed preliminary predictive potential (AUC = 0.909). Bootstrap internal validation supported the stability of the overall predictive performance (empirical P < 0.05). Indicative screening efficiency estimation yielded a number needed to screen (NNS) of 252 to prevent one case of ATDIA.
conclusionATDIA and ATDIN possess distinct genetic mechanisms. Pretherapeutic screening using this population-specific, multi-locus model may offer a preliminary but promising pharmacovigilance strategy for preventing life-threatening ATDIA.
trial registrationChinese Clinical Trial Registry (ChiCTR1900028690, registered on 31 December 2019).
Indexed as
Identifiers
42432373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.